BNGO Quote, Financials, Valuation and Earnings

Azenta has a net margin of -48.04% compared to Bionano Genomics's net margin of -28.21%. Bionano Genomics's return on equity of -141.6% beat Azenta's return on equity of -3.48%.

Bionano Genomics has a consensus price target of $7.33, signalling upside risk potential of 94.52%. On the other hand Azenta has an analysts' consensus of $41.60 which suggests that it could grow by 50.07%. Given that Bionano Genomics has higher upside potential than Azenta, analysts believe Bionano Genomics is more attractive than Azenta.

Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Azenta has a beta of 1.638, suggesting its more volatile than the S&P 500 by 63.767%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.5M, which are smaller than Azenta quarterly revenues of $143.4M. Bionano Genomics's net income of -$3.1M is higher than Azenta's net income of -$40.5M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.16x versus 2.10x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -48.04% compared to Bionano Genomics's net margin of 2.17%. Bionano Genomics's return on equity of -141.6% beat Bruker's return on equity of 4.53%.

Bionano Genomics has a consensus price target of $7.33, signalling upside risk potential of 94.52%. On the other hand Bruker has an analysts' consensus of $55.13 which suggests that it could grow by 48.4%. Given that Bionano Genomics has higher upside potential than Bruker, analysts believe Bionano Genomics is more attractive than Bruker.

Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.54% to investors and pays a quarterly dividend of $0.05 per share. Bionano Genomics pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bionano Genomics quarterly revenues are $6.5M, which are smaller than Bruker quarterly revenues of $801.4M. Bionano Genomics's net income of -$3.1M is lower than Bruker's net income of $17.4M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Bruker's PE ratio is 71.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.16x versus 1.63x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -48.04% compared to Bionano Genomics's net margin of -231.19%. Bionano Genomics's return on equity of -141.6% beat Harvard Bioscience's return on equity of -103.83%.

Bionano Genomics has a consensus price target of $7.33, signalling upside risk potential of 94.52%. On the other hand Harvard Bioscience has an analysts' consensus of $3.00 which suggests that it could grow by 703.64%. Given that Harvard Bioscience has higher upside potential than Bionano Genomics, analysts believe Harvard Bioscience is more attractive than Bionano Genomics.

Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.5M, which are smaller than Harvard Bioscience quarterly revenues of $21.8M. Bionano Genomics's net income of -$3.1M is higher than Harvard Bioscience's net income of -$50.3M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.16x versus 0.18x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies has a net margin of -48.04% compared to Bionano Genomics's net margin of --. Bionano Genomics's return on equity of -141.6% beat Kestra Medical Technologies's return on equity of --.

Bionano Genomics has a consensus price target of $7.33, signalling upside risk potential of 94.52%. On the other hand Kestra Medical Technologies has an analysts' consensus of $27.50 which suggests that it could grow by 22.11%. Given that Bionano Genomics has higher upside potential than Kestra Medical Technologies, analysts believe Bionano Genomics is more attractive than Kestra Medical Technologies.

Bionano Genomics has a beta of 2.367, which suggesting that the stock is 136.713% more volatile than S&P 500. In comparison Kestra Medical Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Kestra Medical Technologies pays out -1.99% of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.5M, which are larger than Kestra Medical Technologies quarterly revenues of --. Bionano Genomics's net income of -$3.1M is higher than Kestra Medical Technologies's net income of --. Notably, Bionano Genomics's price-to-earnings ratio is -- while Kestra Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.16x versus 22.51x for Kestra Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.